RhumbLine Advisers’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-103,239
| Closed | -$4.9M | – | 4132 |
|
|
2025
Q3 | $4.9M | Sell |
103,239
-4,199
| -4% | -$203K | ﹤0.01% | 1453 |
|
|
2025
Q2 | $5.73M | Sell |
107,438
-3,249
| -3% | -$148K | ﹤0.01% | 1335 |
|
|
2025
Q1 | $4.48M | Buy |
110,687
+5,001
| +5% | +$212K | ﹤0.01% | 1416 |
|
|
2024
Q4 | $2.94M | Buy |
105,686
+1,310
| +1% | +$39.7K | ﹤0.01% | 1691 |
|
|
2024
Q3 | $2.99M | Sell |
104,376
-2,962
| -3% | -$77.2K | ﹤0.01% | 1680 |
|
|
2024
Q2 | $2.52M | Buy |
107,338
+24,940
| +30% | +$533K | ﹤0.01% | 1769 |
|
|
2024
Q1 | $2.08M | Buy |
82,398
+11,699
| +17% | +$281K | ﹤0.01% | 1897 |
|
|
2023
Q4 | $1.65M | Sell |
70,699
-85
| -0.1% | -$1.68K | ﹤0.01% | 2006 |
|
|
2023
Q3 | $3.58M | Buy |
70,784
+9,610
| +16% | +$447K | ﹤0.01% | 1534 |
|
|
2023
Q2 | $2.86M | Buy |
61,174
+6,303
| +11% | +$289K | ﹤0.01% | 1707 |
|
|
2023
Q1 | $2.1M | Buy |
54,871
+3,158
| +6% | +$141K | ﹤0.01% | 1784 |
|
|
2022
Q4 | $2.83M | Buy |
51,713
+9,452
| +22% | +$405K | ﹤0.01% | 1608 |
|
|
2022
Q3 | $1.44M | Buy |
42,261
+2,675
| +7% | +$40.9K | ﹤0.01% | 1948 |
|
|
2022
Q2 | $374K | Buy |
39,586
+13,166
| +50% | +$137K | ﹤0.01% | 2637 |
|
|
2022
Q1 | $375K | Buy |
26,420
+765
| +3% | +$13.4K | ﹤0.01% | 2550 |
|
|
2021
Q4 | $543K | Sell |
25,655
-546
| -2% | -$12.1K | ﹤0.01% | 2470 |
|
|
2021
Q3 | $586K | Buy |
26,201
+1,175
| +5% | +$26.6K | ﹤0.01% | 2473 |
|
|
2021
Q2 | $621K | Buy |
25,026
+11,376
| +83% | +$320K | ﹤0.01% | 2459 |
|
|
2021
Q1 | $396K | Sell |
13,650
-750
| -5% | -$22.7K | ﹤0.01% | 2594 |
|
|
2020
Q4 | $372K | Buy |
14,400
+1,270
| +10% | +$35.3K | ﹤0.01% | 2570 |
|
|
2020
Q3 | $404K | Buy |
13,130
+1,684
| +15% | +$58.9K | ﹤0.01% | 2386 |
|
|
2020
Q2 | $285K | Buy |
+11,446
| New | +$262K | ﹤0.01% | 2595 |
|
Other funds holding AKRO
RhumbLine Advisers's AKRO Position: Q4 2025 in Review
RhumbLine Advisers sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 103,239 shares — an estimated $4.9M sold.
RhumbLine Advisers first reported a position in AKRO in Q2 2020 and held it in 22 quarters. The position peaked at $5.73M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- RhumbLine Advisers reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- RhumbLine Advisers sold 103,239 Akero Therapeutics shares in Q4 2025, an estimated $4.9M.
- RhumbLine Advisers first reported a position in Akero Therapeutics in Q2 2020 and held it in 22 quarters.
- RhumbLine Advisers's Akero Therapeutics position peaked at $5.73M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on RhumbLine Advisers's 13F filing for Q4 2025, filed 13 Feb 2026.